Maria Rivera Paz
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Maria Rivera Paz has a total of 48 co-authors. Here are the top co-authors by number of shared publications:
Alan Osvaldo Espinal Martinez
Fundacion Parkinson Puerto Rico
1 shared publicationAmin Cervantes-Arriaga
Laboratorio Clínico de Enfermedades Neurodegenerativas, Instituto Nacional de Neurología y Neurocirugía
1 shared publicationAndrew Pieper
Case Western Reserve University
1 shared publication- Artur Francisco Schumacher Schuh
Universidade Federal do Rio Grande do Sul
1 shared publication Beatriz Munoz Ospina
Human Sciences Department, Universidad Icesi
1 shared publication- Bruno Lopes Santos-Lobato
Laboratório de Neuropatologia Experimental, Universidade Federal do Pará, Belém, Brazil
1 shared publication
Latest Publications
- Open Access
Genomic Landscape of Early-Onset and Familial Latin American Parkinson’s Patients
Background: Parkinson’s disease (PD), the most common neurodegenerative movement disorder, is commonly thought of as an aging and sporadic disease; however, 5-14% of individuals experience disease onset before the age of 50 years (early-onset PD; EOPD) and about 20% have a positive family history. In the case of both EOPD and people with a family history of PD, evidence suggests higher rates of a disease-causing genetic contribution. Objectives: Our goal was to perform a variant screening of seven PD-related genes and 21 genes associated with related parkinsonian disorders to identify pathogenic/likely pathogenic variants and variants of uncertain significance within EOPD and family-history-positive individuals within the Latin American Research Consortium on the Genetics of PD (LARGE-PD). Methods: We performed short-read whole-genome sequencing on a subset of 263 individuals with EOPD and/or a familial history of PD who had no known pathogenic PD variant in genotyping data. Results: Of the analyzed individuals, a monogenic burden in primary and secondary PD genes due to pathogenic or likely pathogenic variants for PD was observed in 4.7%, an additional 5.5% had pathogenic or likely pathogenic variants for Gaucher’s disease, and 2.7% had known risk variants in GBA1 . Conclusions: By expanding the reported spectrum of disease-associated variants in a Latin American population, we identified previously unreported or underrepresented variants that would likely be missed by array-based or targeted screening approaches and contribute to the characterization of EOPD and familial PD in Latin America.
Open AccessGenomic Landscape of Early-Onset and Familial Latin American Parkinson’s Patients
Background: Parkinson’s disease (PD), the most common neurodegenerative movement disorder, is commonly thought of as an aging and sporadic disease; however, 5-14% of individuals experience disease onset before the age of 50 years (early-onset PD; EOPD) and about 20% have a positive family history. In the case of both EOPD and people with a family history of PD, evidence suggests higher rates of a disease-causing genetic contribution. Objectives: Our goal was to perform a variant screening of seven PD-related genes and 21 genes associated with related parkinsonian disorders to identify pathogenic/likely pathogenic variants and variants of uncertain significance within EOPD and family-history-positive individuals within the Latin American Research Consortium on the Genetics of PD (LARGE-PD). Methods: We performed short-read whole-genome sequencing on a subset of 263 individuals with EOPD and/or a familial history of PD who had no known pathogenic PD variant in genotyping data. Results: Of the analyzed individuals, a monogenic burden in primary and secondary PD genes due to pathogenic or likely pathogenic variants for PD was observed in 4.7%, an additional 5.5% had pathogenic or likely pathogenic variants for Gaucher’s disease, and 2.7% had known risk variants in GBA1 . Conclusions: By expanding the reported spectrum of disease-associated variants in a Latin American population, we identified previously unreported or underrepresented variants that would likely be missed by array-based or targeted screening approaches and contribute to the characterization of EOPD and familial PD in Latin America.
- Open Access
- 26 February 2026
- Published by Springer Nature in Research Square
Neuronal and microglial fine-tuned 3D DNA foundation models dissect genetic variants in Alzheimer’s disease
Although genetic variants are among the strongest risk factors for Alzheimer’s disease (AD), most associated variants reside in non-coding regions with unclear mechanisms. Here, we address that gap by fine-tuning the Akita DNA foundation model on high-resolution Hi-C data generated from neuronal progenitor cells (NPCs) and microglia to produce iNeuroAkita , a cell-context-aware three-dimensional (3D) genome model. iNeuroAkita shows improved correlation with experimental Hi-C contact maps and more accurate contact predictions at key AD loci (e.g. APOE and PSEN2) , and captures CTCF-dependent chromatin loops. Using in silico saturation mutagenesis (ISM) across 11,856 AD-associated single-nucleotide variants (SNVs) and 120 structural variants (SVs), we quantified impacts on chromatin spatial organization and identified two SNVs predicted to strongly disrupt 3D chromatin architecture: rs636317 at the MS4A locus that is predicted to disrupt local chromatic interactions and microglia eQTL rs7599054 that creates gained interactions connecting its surrounding region to CCNT2 and TMEM163 , consistent with enhancer–promoter activation in epigenomic and single-cell transcriptomic data. We also identified AD-associated deletions at the KANSL1 and ARMS2 that rewire local regulatory contacts and associate with cell-type-specific expression changes, demonstrating iNeuroAkita’s utility for systematic characterization of noncoding AD risk variants underlying 3D genome regulation.
- 26 February 2026
- Published by Springer Nature in Research Square
Open AccessNeuronal and microglial fine-tuned 3D DNA foundation models dissect genetic variants in Alzheimer’s disease
Although genetic variants are among the strongest risk factors for Alzheimer’s disease (AD), most associated variants reside in non-coding regions with unclear mechanisms. Here, we address that gap by fine-tuning the Akita DNA foundation model on high-resolution Hi-C data generated from neuronal progenitor cells (NPCs) and microglia to produce iNeuroAkita , a cell-context-aware three-dimensional (3D) genome model. iNeuroAkita shows improved correlation with experimental Hi-C contact maps and more accurate contact predictions at key AD loci (e.g. APOE and PSEN2) , and captures CTCF-dependent chromatin loops. Using in silico saturation mutagenesis (ISM) across 11,856 AD-associated single-nucleotide variants (SNVs) and 120 structural variants (SVs), we quantified impacts on chromatin spatial organization and identified two SNVs predicted to strongly disrupt 3D chromatin architecture: rs636317 at the MS4A locus that is predicted to disrupt local chromatic interactions and microglia eQTL rs7599054 that creates gained interactions connecting its surrounding region to CCNT2 and TMEM163 , consistent with enhancer–promoter activation in epigenomic and single-cell transcriptomic data. We also identified AD-associated deletions at the KANSL1 and ARMS2 that rewire local regulatory contacts and associate with cell-type-specific expression changes, demonstrating iNeuroAkita’s utility for systematic characterization of noncoding AD risk variants underlying 3D genome regulation.